# Nuclide record abdera-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/abdera-therapeutics/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "abdera-therapeutics" ;
  schema:name "Abdera Therapeutics"@en ;
  schema:description "Abdera Therapeutics engineered antibodies that carry a radioactive isotope to cancer cells, tuning how long they circulate so more radiation reaches the tumour and less reaches healthy tissue. Its first medicine targets a protein on small cell lung cancer."@en ;
  schema:url <https://nuclide.cc/companies/abdera-therapeutics/>, <https://www.biospace.com/abdera-therapeutics-debuts-with-142-million-in-financing-to-engineer-and-advance-best-in-class-antibody-based-radiopharmaceuticals-for-cancer> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.biospace.com/abdera-therapeutics-debuts-with-142-million-in-financing-to-engineer-and-advance-best-in-class-antibody-based-radiopharmaceuticals-for-cancer>, <https://endpoints.news/abdera-raises-110m-to-push-targeted-radiotherapies-where-they-havent-gone-before/> ;
  schema:addressCountry "CA" ;
  nuclide:indications <https://nuclide.cc/indications/sclc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioimmunotherapy/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/technologies/radioligand-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/dll3/> .